Related Experiment Videos
microRNA-206 correlates with left ventricular function after transcatheter aortic valve implantation.
J A Kleeberger1, J Neuser2, D de Gonzalo-Calvo1,3,4
1Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School , Hannover , Germany.
American Journal of Physiology. Heart and Circulatory Physiology
|October 15, 2017
Summary
Researchers identified miR-206 as a potential biomarker for cardiac function after transcatheter aortic valve implantation (TAVI). Lower miR-206 levels post-TAVI indicate better left ventricular function, suggesting its prognostic value.
Area of Science:
- Cardiology
- Molecular Biology
- Biomarker Discovery
Background:
- Transcatheter aortic valve implantation (TAVI) is a key treatment for high-risk patients with aortic valve disease.
- Predicting postprocedural cardiac function after TAVI remains a challenge.
- MicroRNAs (miRNAs) are emerging as potential blood-based biomarkers for various diseases.
Purpose of the Study:
- To investigate serum miRNA levels as predictors of cardiac function following TAVI.
- To identify specific miRNAs that correlate with left ventricular ejection fraction post-TAVI.
Main Methods:
- Serum samples were collected from patients undergoing TAVI at multiple time points (pre-procedure, post-procedure days 1 & 3, discharge, 3 months).
- Quantitative real-time PCR was used to measure the levels of cardiac-enriched miRNAs.
- Statistical analysis correlated miRNA levels with left ventricular ejection fraction.
Main Results:
- Serum miR-206 levels showed a significant negative correlation with left ventricular ejection fraction after TAVI.
- Patients with lower post-TAVI miR-206 levels exhibited improved left ventricular function.
- A decrease in serum miR-206 may indicate improved cardiac function post-procedure.
Conclusions:
- miR-206 is a potential novel biomarker for assessing cardiac function after TAVI.
- Further research is warranted to validate miR-206 as a prognostic marker in TAVI patients.